Vascular smooth muscle cell relaxation (null)

The process of "direct vasodilation via smooth muscle relaxation" refers to the mechanism by which blood vessel diameter increases due to the relaxation of smooth muscle cells in the vessel wall. This effect underlies the action of many antihypertensive and antianginal drugs. Smooth muscle relaxation is mediated by several molecular pathways, including decreased intracellular calcium concentration, activation of myosin light-chain phosphatase (MLCP), and increased production of second messengers (cGMP via nitric oxide, cAMP via β2-adrenergic or adenosine receptors). Drugs that enhance these pathways (e.g., nitrates, hydralazine, calcium channel blockers) are clinically useful for diseases related to increased vascular tone such as hypertension and heart failure[1][2][4][8][10]. However, "direct vasodilation via smooth muscle relaxation" itself does not denote a molecular target but refers to the collective outcome of several molecular mechanisms. If you are seeking information about specific molecular targets involved in this process (e.g., myosin light-chain phosphatase, β2-adrenergic receptor, NO receptor, L-type calcium channel), they should be individually referenced and named according to their canonical forms.

Other names

VasodilationVascular smooth muscle relaxationDirect vasodilation mechanism

Increased NO signaling (activates guanylyl cyclase → cGMP ↑ → PKG activation → MLCP activation → myosin dephosphorylation → relaxation) Increased cAMP signaling (via β2-adrenergic or adenosine receptors) Inhibition of calcium influx (blockade of L-type calcium channels) Direct activation of MLCP or other phosphatases